Having established that RAD54-BLM interaction caused chemoresistance in colon cancer cells, we reasoned that breaking the RAD54-BLM interaction should resensitize colon cancer cells to the chemotherapeutic drugs. Here, ATRX is linked to malignant colon neoplasm.